Efficacy of ezetimibe combined with atorvastatin in early treatment of acute ischemic stroke and its influence on serum levels of absent in melanoma 2 and leukotriene B4
10.3760/cma.j.cn115455-20241206-01087
- VernacularTitle:依折麦布联合阿托伐他汀早期治疗急性缺血性卒中的疗效及对血清黑色素瘤缺乏因子2和白三烯B4水平的影响
- Author:
Na CHEN
1
;
Xuefang CHEN
1
;
Jieshan ZHUANG
1
;
You'an GAO
1
Author Information
1. 东莞市滨海湾中心医院神经内科，东莞 523905
- Publication Type:Journal Article
- Keywords:
Brain infarction;
Atorvastatin;
Ezetimibe;
Neurological impairment;
Prognosis
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(10):884-889
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the efficacy of thrombectomy combined with ezetimibe and atorvastatin in patients with acute ischemic stroke (AIS) and the serum levels of absent in melanoma 2 (AIM2) and leukotriene B4 (LTB4).Methods:A prospective study method was used to select 60 patients with AIS thrombectomy treated in Marina Bay Central Hospital of Dongguan City from June 2021 to December 2022, and they were divided into two groups according to random number table method, with 30 cases in each group. The control group was given atorvastatin treatment, and the study group was combined with ezetimibe treatment on the basis of the control group treatment. Blood routine indexes, blood lipid indexes and serum levels of AIM2 and LTB4 were compared between the two groups at admission, discharge and follow-up for 3 months. The National Institutes of Health Stroke Scale (NIHSS) was used to assess the degree of neurological impairment of the patients, and the modified Rankin Scale (mRS) was used to assess the patients' ability to live independently. The occurrence of adverse reactions in the two groups was observed and compared.Results:The neutrophil to lymphocyte ratio (NLR) and neutrophil (N) in the study group were lower than those in the control group : 1.71 ± 0.05 vs. 2.04 ± 0.31, 0.261 ± 0.012 vs. 0.403 ± 0.021 at follow-up for 3 months, there were statistical differences ( P<0.05). The levels of low density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and triacylglycerol (TG) in the study group were lower than those in the control group at follow-up for 3 months:(1.59 ± 0.48) mmol/L vs. (2.09 ± 0.69) mmol/L, (2.92 ± 0.44) mmol/L vs. (3.57 ± 0.71) mmol/L, (1.19 ± 0.24) mmol/L vs. (1.37 ± 0.21) mmol/L, the level of high density lipoprotein cholesterol (HDL-C) was higher than that in the control group : (1.24 ± 0.19) mmol/L vs. (1.06 ± 0.21) mmol/L, there were statistical differences ( P<0.05). The levels of AIM2 and LTB4 in the study group were lower than those in the control group at discharge and follow-up for 3 months: (945.20 ± 123.60) ng/L vs. (1 094.40 ± 227.10) ng/L, (948.90 ± 135.80) ng/L vs. (1 236.90 ± 125.70) ng/L, (115.80 ± 20.60) ng/L vs. (129.70 ± 31.50) ng/L, (116.40 ± 21.10) ng/L vs. (130.30 ± 32.60) ng/L, there were statistical differences (P<0.05). The NHISS scores in the study group was lower than that in the control group at follow-up for 3 months: 2.00(1.00, 3.00) scores vs. 4.00(3.00, 5.00) scores, there was statistical difference ( P<0.05). After follow-up for 3 months, the mRS scores and incidence of adverse reactions between the two groups had no statistical differences ( P<0.05). Conclusions:The combination of atorvastatin and ezetimibe in the early stage of AIS thrombectomy can significantly reduce the levels of NLR, serum AIM2 and LTB4, improve blood lipid levels, reduce the degree of neurological impairment, and improve the ability of patients to carry out activities of daily living, with high safety.
